Source:http://linkedlifedata.com/resource/pubmed/id/17502774
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2007-5-15
|
pubmed:abstractText |
Steady-state plasma concentrations of (R)- (ie, the active form), (S)-, and (R,S)-methadone were measured in 14 addict patients in methadone maintenance treatment, before and after introduction of quetiapine, administered at a mean dosage of 138 mg/d (SD, 87 mg/d; median, 125 mg/d; range, 50-300 mg/d) during a mean period of 30 days (SD, 8 days; median, 30 days; range, 20-48 days). Eleven patients were genotyped as being CYP2D6 extensive metabolizers (EMs) and 3 patients as poor metabolizers. Eleven patients had the ABCB1 3435 CT or CC genotypes, and 3 patients had the ABCB1 3435 TT genotype, the latter genotype being associated with lower P-glycoprotein activity. Quetiapine significantly increases (R)-methadone concentration-dose ratios in the whole group [increase for (R)-methadone: mean, +21%; SD, +28%; median, +13%; range, -23% to +85%; P = 0.026], but not for (S)-methadone (mean, +23%; SD, +43%; median, +6%; range, -30% to +115%; P = 0.12) or for (R,S)-methadone (mean, +21%; SD, +34%; median, +9%; range, -21% to +95%; P = 0.064). The mean increases of (R)-methadone concentration-dose ratios were of 7%, 21%, and 30% in the CYP2D6 poor metabolizers, heterozygous EMs, and homozygous EMs, respectively, whereas they were of 3%, 23%, and 33% in the subjects with the ABCB1 3435 TT, CT, and CC genotypes, respectively. Thus, quetiapine increases the plasma concentrations of (R)-methadone, possibly in part by an interaction with CYP2D6 and/or with the P-glycoprotein transporter system. No signs of overmedication caused by increased methadone plasma concentrations were noticed by the staff or reported by the patients.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/ABCB1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Antipsychotic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 Enzyme System,
http://linkedlifedata.com/resource/pubmed/chemical/Dibenzothiazepines,
http://linkedlifedata.com/resource/pubmed/chemical/Isoenzymes,
http://linkedlifedata.com/resource/pubmed/chemical/Methadone,
http://linkedlifedata.com/resource/pubmed/chemical/Narcotics,
http://linkedlifedata.com/resource/pubmed/chemical/Organic Anion Transporters,
http://linkedlifedata.com/resource/pubmed/chemical/P-Glycoprotein,
http://linkedlifedata.com/resource/pubmed/chemical/quetiapine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0271-0749
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
27
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
273-8
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:17502774-Adult,
pubmed-meshheading:17502774-Antipsychotic Agents,
pubmed-meshheading:17502774-Cytochrome P-450 Enzyme System,
pubmed-meshheading:17502774-Dibenzothiazepines,
pubmed-meshheading:17502774-Drug Interactions,
pubmed-meshheading:17502774-Female,
pubmed-meshheading:17502774-Humans,
pubmed-meshheading:17502774-Isoenzymes,
pubmed-meshheading:17502774-Male,
pubmed-meshheading:17502774-Methadone,
pubmed-meshheading:17502774-Middle Aged,
pubmed-meshheading:17502774-Narcotics,
pubmed-meshheading:17502774-Opioid-Related Disorders,
pubmed-meshheading:17502774-Organic Anion Transporters,
pubmed-meshheading:17502774-P-Glycoprotein,
pubmed-meshheading:17502774-Phenotype,
pubmed-meshheading:17502774-Polymorphism, Genetic,
pubmed-meshheading:17502774-Stereoisomerism
|
pubmed:year |
2007
|
pubmed:articleTitle |
Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients.
|
pubmed:affiliation |
Centre Psychosocial, Unité de Traitement des Addictions, Fribourg, Switzerland.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|